EVMN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

13.900

Open

12.970

VWAP

13.12

Vol

1.34M

Mkt Cap

466.80M

Low

12.510

Amount

17.64M

EV/EBITDA(TTM)

Total Shares

36.02M

256.43M

EV/OCF(TTM)

P/S(TTM)

Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Events Timeline

(ET)

2026-06-29

16:30:00

Major Averages Finish Broadly Higher as Investors Await Middle East News

2026-06-29

12:00:00

Major Averages Broadly Higher as Investors Await Middle East News

2026-06-29

09:00:00

Evommune Announces Phase 2b Trial Results for EVO756

2026-06-22 (ET)

2026-06-22

07:00:00

Canaccord Analyst Says AbbVie's $10.9B Acquisition of Apogee Worth $144 per Share

News

7.0

06-30Newsfilter

Evommune Shares Plunge 38% After Drug Trial Failure

7.0

06-30PRnewswire

Evommune Executives Under Investigation for Insider Trading Ahead of Drug Trial Failure

9.0

06-29seekingalpha

Evommune Shares Drop 31% After Phase 2b Trial Misses Primary Endpoint

9.0

06-29NASDAQ.COM

Evommune Reports Phase 2b Trial Results for EVO756

9.0

06-29Newsfilter

Evommune's Clinical Trial Fails to Meet Primary Endpoint

9.5

05-08seekingalpha

Evommune, Inc. Reports Q1 Financial Results

7 Analyst Rating

Wall Street analysts forecast EVMN stock price to rise

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

35.00

Averages

38.60

High

42.00

Current: 0.000

Low

35.00

Averages

38.60

High

42.00

H.C. Wainwright

Mitchell Kapoor

Buy

Neutral

downgrade

$NULL

AI Analysis

2026-06-30

New

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$NULL

AI Analysis

2026-06-30

New

downgrade

Buy

Neutral

Reason

H.C. Wainwright analyst Mitchell Kapoor downgraded Evommune to Neutral from Buy without a price target after EVO756 failed to meet the Phase 2b primary endpoint. This is \"materially damaging\" to Evommune because chronic spontaneous urticaria was the lead EVO756 indication, the analyst tells investors in a research note.

Morgan Stanley

Overweight

downgrade

$55 -> $26

2026-06-30

New

Reason

Morgan Stanley

Price Target

$55 -> $26

2026-06-30

New

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Evommune to $26 from $55 and keeps an Overweight rating on the shares after the failure of its lead asset, EVO756, in a Phase 2b study of its lead indication, chronic spontaneous urticaria. While removing '756 from the firm's model, the firm maintains an Overweight rating as EVO301 data in atopic dermatitis reported earlier this year "remain encouraging" and the mechanistic rationale for EVO756 in migraine "represents medium-term optionality for the asset," the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVMN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evommune Inc (EVMN.N) is 0.00, compared to its 5-year average forward P/E of -5.84. For a more detailed relative valuation and DCF analysis to assess Evommune Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.84

Current PE

0.00

Overvalued PE

-5.35

Undervalued PE

-6.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-137.50

Current EV/EBITDA

-43.24

Overvalued EV/EBITDA

-46.17

Undervalued EV/EBITDA

-228.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

747.58

Current PS

373.44

Overvalued PS

1042.15

Undervalued PS

453.02

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

WEEKLY RSI>60

Intellectia · 4308 candidates

Rsi Category: moderate

Ticker

Name

Market Cap$

CCHH

CCH Holdings Ltd

15.56M

JZXN

Jiuzi Holdings Inc

1.87M

HURA

TuHURA Biosciences Inc

48.38M

KELYB

Kelly Services Inc

702.89M

BRLS

Borealis Foods Inc

28.33M

SMX

SMX (Security Matters) PLC

149.88M

Whales Holding EVMN

Sofinnova Investments, Inc.

RA Capital Management, L.P.

Kynam Capital Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evommune Inc (EVMN) stock price today?

The current price of EVMN is 12.96 USD — it has increased 1.09

What is Evommune Inc (EVMN)'s business?

What is the price predicton of EVMN Stock?

Wall Street analysts forecast EVMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVMN is38.60 USD with a low forecast of 35.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.